INSIGHTS ON QUALITY CONTROL

• Improving Bioprocess Monitoring And Control With Multivariate Data Analysis

  Learn about multivariate data analysis (MVDA) techniques, like PCA and PLS, that enable near real-time monitoring, prediction, and optimization of biomanufacturing processes.

• Elevating Environmental Monitoring Trending: From Data To Insight

  Move beyond raw data by using heat maps and site-specific limits to identify contamination hotspots. Transform your environmental monitoring into a proactive strategy for operational excellence.

• Optimizing Contamination Control: Strategy Planning And Execution

  A robust contamination control strategy using a plan-do-study-act framework ensures compliance, product quality, and operational efficiency in biopharmaceutical manufacturing facilities.

• A Guide To Scale-Up And Purification For Small, Large Molecules

  Advance your separation and purification strategies by leveraging modern industrial chromatography approaches that scale reliably from lab to production across small-molecule and biologics manufacturing.

• Physical Contamination Detection

  3/23/2026

  Learn how physical contaminants enter production lines and how detection systems like metal detection and X-ray inspection help prevent defects and recalls to strengthen quality control.

• Effect Of X-Ray Inspection On Pharmaceutical Products

  7/23/2024

  Explore the use of X-ray inspection systems for the internal examination of pharmaceutical products, particularly non-transparent packaged drugs.

• Understanding FDA Calibration Requirements And Best Practices For Reducing Risks

  10/2/2024

  Become equipped with the tools and strategies needed to strengthen your calibration efforts and better position your organization for success in regulatory audits.

• Quantifying Endotoxins Via Absorbance Or Fluorescence

  3/20/2026

  Find out how endotoxin assays use Factor C activation to generate measurable absorbance or fluorescence signals, with guidance on selecting detection formats and implementing scalable workflows.

• The Seamless Path To Market: End-To-End CDMOs As Your Strategic Ally Douglas CDMO

  5/14/2025

  Partner with an experienced end-to-end CDMO to streamline development, reduce risk, and accelerate your drug’s path to market in today’s complex and competitive pharmaceutical landscape.